Status:
COMPLETED
The Clinical Trial of ADR-001 for IgA Nephropathy
Lead Sponsor:
Nagoya University
Collaborating Sponsors:
Rohto Pharmaceutical Co., Ltd.
Conditions:
Glomerulonephritis , IGA
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and the tolerability of ADR-001 in Immunoglobulin A (IgA) Nephropathy patients. In addition, the investigators will evaluate the efficacy of ADR-001...
Eligibility Criteria
Inclusion
- IgA nephropathy diagnosed by renal biopsy.
- Meet any of the following criteria.
- i. Urinary protein at screening is 0.5 g / gCr or more and eGFR is 60 mL / min / 1.73m\^2 or more even if corticosteroids are used for 6 months or more before screening.
- ii. Urine protein of 1.0 g / gCr or more and eGFR of 30 mL / min / 1.73 m\^2 or more and less than 60 mL / min / 1.73 m\^2 at screening even if corticosteroids are used for 6 months or more before screening.
- iii. Urine protein of 0.5 g / gCr or more and less than 1.0 g / gCr at screening and eGFR of 20 mL / min / 1.73m\^2 or more and 60 mL / min / 1.73m\^2 or urine protein of 1.0 g / gCr or more at screening And eGFR is 20 mL / min / 1.73m\^2 or more and less than 30 mL / min / 1.73m\^2.
- Over 20 years old.
- Able to provide informed consent.
- However, in the first cohort, only 2) -i is applied in the selection criteria 2), and in the second cohort, 2) -i, ii, and iii are applied.
Exclusion
- Nephropathy other than IgA nephropathy, and primary and secondary nephrotic syndrome.
- Start or increase drug therapy for IgA nephropathy with corticosteroids, immunosuppressants, renin angiotensin system (RAS ) inhibitors, antiplatelet drugs, anticoagulants (warfarin), and n-3 fatty acids (fish oil) within 3 months . Palatal tonsillectomy within 6 months.
- Treatment with other cells.
- Participated within 3 months or participating in other clinical trials .
- Penal transplantation within 3 years or scheduled.
- Diabetics not well controlled.
- Malignant neoplasm or history of malignant neoplasm within 5 years, or judged possibility of malignant tumor.
- Suspected of active infection.
- Positive for hepatitis B (HB), hepatitis C virus (HCV),human Immunodeficiency virus (HIV), human T-cell leukemia virus 1 (HTLV-1) or syphilis.
- History of severe hypersensitivity or anaphylactic reaction.
- Allergic to penicillin antibiotics, aminoglycoside antibiotics or dimethyl sulfoxide (DMSO).
- Serious complications not related to IgA nephropathy.
- Bleeding or may bleed, shallow days after surgery or trauma to the central nervous system, history of hypersensitivity to components of heparin preparations, history of heparin-induced thrombocytopenia Previous patient.
- During pregnancy, lactation, may be pregnant or both men and women who do not agree to give birth control under the guidance of the investigator or investigator during the study period.
Key Trial Info
Start Date :
June 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04342325
Start Date
June 15 2020
End Date
March 31 2023
Last Update
May 1 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasugai Municipal Hospital
Kasugai, Aichi-ken, Japan, 486-8510
2
Nagoya University Hospital
Nagoya, Aichi-ken, Japan, 566-8560